Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.
OncLive’s April Roundup of Key FDA Decisions in Oncology
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer